The assessment of curcumin in comparison with placebo on the auditory neuropathy in chronic kidney disease and diabetes mellitus patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210620051629N1

Enrollment

Registered

2021-08-18

Start date

2021-08-23

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease. Chronic kidney disease (CKD)

Interventions

Intervention 1: Intervention group: Daily consumption of one capsule of 500 mg of turmeric extract (containing 475 mg of curcuminoid, Karen Company) for 8 weeks. Intervention 2: Control group: Daily c

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: All chronic kidney and diabetic patients with definitive diagnosis of nephrologist and endocrinologist who have been ill for more than 6 months All patients with chronic renal disease and diabetes with definitive diagnosis who have hearing impairment in the initial evaluation All chronic renal and diabetic patients with definitive diagnosis with glomerular filtration rate less than 60

Exclusion criteria

Exclusion criteria: Use of aspirin and warfarin Mental diseases Usage of other complementary medicine methods Pregnancy lactation Usage of other antioxidant drugs except Nephrovit pills Having gallstones

Design outcomes

Primary

Measure	Time frame
Hearing threshold based on auditory brain stem responses (ABR). Timepoint: Before intervention, After intervention. Method of measurement: Minimum hearing threshold based on auditory brain stem responses (ABR).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAida Doostkam

Shiraz University of Medical Sciences

doostkam@sums.ac.ir+98 71 3235 7282

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026